Eosinophilic Granuloma Complex

Eosinophilic Granuloma Complex (EGC) is a group of inflammatory skin and oral mucosal lesions in cats, characterized by eosinophilic infiltration, granulomatous inflammation, and collagen degeneration. The complex encompasses three classic clinical forms: indolent ulcer (rodent ulcer), eosinophilic plaque, and eosinophilic granuloma (linear granuloma). While primarily a dermatologic disorder, oral manifestations are common and significant, presenting as raised, ulcerated, or proliferative lesions on the lips, tongue, palate, and pharynx. EGC is considered a hypersensitivity reaction to various allergens, including flea bites, food components, and environmental allergens. The condition is not a single disease but a reactive pattern with multiple etiologies, and its pathogenesis involves a dysregulated type I (immediate) and type IV (delayed) hypersensitivity response, leading to eosinophil degranulation and tissue damage. Oral EGC can cause significant morbidity, including dysphagia, anorexia, and secondary infections, and may mimic neoplastic or infectious diseases, necessitating thorough diagnostic evaluation.

The exact etiology of EGC is multifactorial, with hypersensitivity reactions playing a central role. Primary triggers include: 1) Flea allergy dermatitis (most common in some regions), 2) Food allergy (adverse food reaction) to specific proteins (e.g., beef, dairy, fish, chicken), 3) Atopy (environmental allergens such as pollens, molds, dust mites), 4) Mosquito bite hypersensitivity (especially for lesions on the nasal planum and ears), 5) Genetic predisposition (some breeds, e.g., Siamese and related breeds, are overrepresented), 6) Concurrent viral infections (e.g., feline herpesvirus-1, feline calicivirus, feline leukemia virus, feline immunodeficiency virus) may act as cofactors or triggers, 7) Bacterial infections (secondary, not primary), 8) Stress and psychogenic factors may exacerbate lesions, 9) Idiopathic causes when no specific allergen is identified. The immunopathogenesis involves allergen cross-linking of IgE on mast cells, leading to degranulation and release of histamine, eosinophil chemotactic factors, and cytokines. Eosinophils are recruited to the site, where they degranulate and release major basic protein, eosinophil peroxidase, and collagenase, causing tissue damage and granuloma formation. In chronic lesions, a Th2-dominant immune response with IL-4, IL-5, and IL-13 production perpetuates eosinophilic inflammation.

EGC is primarily a disease of cats, with no age or sex predilection, though young adults (2-6 years) may be more commonly affected. Certain breeds, including Siamese, Himalayan, and domestic shorthair cats, may have a genetic predisposition. The condition is seen worldwide, but the prevalence of specific triggers varies geographically; for example, flea allergy is more common in humid climates, while mosquito bite hypersensitivity is seen in outdoor cats in warmer regions. Oral lesions are reported in a significant proportion of cats with EGC, with some studies suggesting that up to 50% of cats with EGC have oral involvement. There is no clear seasonal pattern, but lesions may flare in seasons with high allergen exposure (e.g., spring and summer for pollens, summer for fleas). The condition is not contagious, and there is no known zoonotic potential. In multi-cat households, no direct transmission occurs, but shared environmental allergens may affect multiple cats.

The pathophysiology of EGC involves a complex interplay between genetic susceptibility, allergen exposure, and immune dysregulation. Upon allergen exposure, antigen-presenting cells (Langerhans cells in the skin and oral mucosa) process and present allergens to T lymphocytes, promoting a Th2 phenotype. Th2 cells secrete IL-4, IL-5, and IL-13, which stimulate B cells to produce IgE and promote eosinophil differentiation, activation, and survival. IgE binds to high-affinity receptors (FcεRI) on mast cells and basophils. Subsequent allergen exposure cross-links IgE, triggering mast cell degranulation and release of histamine, leukotrienes, prostaglandins, and eosinophil chemotactic factors (e.g., eotaxin). Eosinophils migrate to the tissue, where they become activated and release cytotoxic granules containing major basic protein, eosinophil cationic protein, eosinophil peroxidase, and collagenase. These mediators cause tissue necrosis, collagen degeneration, and granulomatous inflammation. In oral lesions, the epithelium may ulcerate, and the underlying connective tissue shows eosinophilic infiltration, flame figures (collagen fibers coated with eosinophilic debris), and granuloma formation. Chronic inflammation can lead to fibrosis and scarring. Secondary bacterial infection may complicate the lesions, exacerbating inflammation and delaying healing. The exact reason why some cats develop oral lesions versus cutaneous lesions is unknown, but local factors such as trauma, dental disease, or viral infections may influence the site of manifestation.

Predisposing factors for EGC include: 1) Genetic predisposition: certain breeds (Siamese, Himalayan, and their crosses) have a higher incidence, suggesting an inherited tendency for hypersensitivity. 2) Age: young adult cats are more commonly affected, though any age can be seen. 3) Environmental allergens: exposure to fleas, mosquitoes, pollens, molds, and house dust mites increases risk. 4) Dietary factors: food allergies to specific protein sources (beef, dairy, fish, chicken, etc.) are common triggers. 5) Concurrent viral infections: infection with feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), feline herpesvirus-1 (FHV-1), or feline calicivirus (FCV) may immunosuppress or dysregulate the immune system, increasing susceptibility. 6) Stress: psychological stress may exacerbate or trigger lesions. 7) Dental disease: pre-existing oral inflammation or dental pathology may predispose to oral EGC lesions. 8) Management factors: outdoor access increases exposure to insect bites and environmental allergens. 9) Immunosuppressive therapy: use of corticosteroids or other immunosuppressants may alter immune responses, potentially triggering lesions. 10) Idiopathic factors: in many cases, no specific trigger is identified.

Clinical signs of oral EGC vary depending on the form and location. Indolent ulcers (rodent ulcers) typically occur on the upper lip, often near the philtrum, and appear as well-demarcated, ulcerated, red-brown lesions with a smooth, raised border. They are usually non-painful but may bleed. Eosinophilic plaques are raised, erythematous, ulcerated, and often pruritic; they can occur on the oral mucosa, tongue, and palate. Eosinophilic granulomas (linear granulomas) present as firm, raised, linear or nodular lesions, often on the tongue, hard palate, or pharynx; they may be ulcerated or have a cobblestone appearance. Cats with oral lesions may show: 1) Dysphagia (difficulty eating), 2) Anorexia or reduced appetite, 3) Ptyalism (excessive drooling), 4) Halitosis, 5) Pawing at the mouth, 6) Weight loss, 7) Gingivitis or stomatitis, 8) Oral bleeding, 9) Reluctance to groom, 10) In severe cases, respiratory signs if pharyngeal involvement causes obstruction. Systemic signs are uncommon unless secondary infection or severe debilitation occurs. Chronic lesions may become fibrotic and non-responsive to therapy. It is important to note that oral EGC can coexist with cutaneous lesions, and a thorough dermatologic examination is warranted.

Differential diagnoses for oral EGC include: 1) Squamous cell carcinoma (SCC): the most common oral tumor in cats; presents as a proliferative, ulcerated mass, often on the tongue or tonsils; diagnosis via biopsy; SCC is locally invasive and has a poor prognosis. 2) Fibrosarcoma: a mesenchymal tumor that can occur in the oral cavity; firm, nodular, may ulcerate; biopsy confirms. 3) Lymphoma: especially in FeLV/FIV-positive cats; can present as oral masses or diffuse infiltration; cytology/histopathology with immunophenotyping. 4) Chronic gingivostomatitis (lymphocytic-plasmacytic stomatitis): severe inflammation of the gingiva and oral mucosa, often associated with calicivirus; lesions are typically bilateral and involve the caudal oral cavity; biopsy shows lymphocytic/plasmacytic infiltration. 5) Eosinophilic granuloma due to other causes (e.g., mosquito bite hypersensitivity) – but this is part of EGC. 6) Foreign body granuloma: due to plant material or other foreign bodies; history of chewing on plants; imaging or surgical exploration may reveal. 7) Bacterial abscess or cellulitis: painful, fluctuant swelling; responds to antibiotics; culture and cytology. 8) Fungal infections (e.g., cryptococcosis, histoplasmosis): systemic signs, cytology/histopathology with fungal stains. 9) Viral papillomatosis: cauliflower-like growths, usually in young cats; biopsy shows papillomavirus-induced changes. 10) Trauma-induced ulceration: history of injury, foreign body, or electrical cord burn; lesions may heal with supportive care. Definitive diagnosis requires biopsy and histopathology, as clinical appearance alone is not pathognomonic.

The diagnostic approach for oral EGC should be systematic: 1) History and physical examination: obtain a thorough history including diet, flea control, outdoor access, and progression of lesions. Perform a complete oral examination under sedation or anesthesia if necessary, to visualize all oral surfaces. 2) Initial laboratory work: complete blood count (CBC), serum biochemistry profile, urinalysis, and feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) testing. Eosinophilia may be present but is not consistent. 3) Skin and oral cytology: impression smears or fine-needle aspirates of lesions may show eosinophils, mast cells, and neutrophils; however, cytology is not definitive. 4) Biopsy: the gold standard for diagnosis. Obtain multiple, deep biopsies from the edge and center of lesions, including underlying tissue. Histopathology typically shows eosinophilic infiltration, flame figures, collagen degeneration, and granulomatous inflammation. 5) Allergy evaluation: if EGC is confirmed, identify underlying allergens. This may include flea control trials (strict, year-round), dietary elimination trials (hypoallergenic diet for 8-12 weeks), and intradermal or serum allergy testing for environmental allergens. 6) Imaging: if there is suspicion of underlying dental disease or bony involvement, dental radiographs or advanced imaging (CT) may be indicated. 7) Rule out other differentials: based on biopsy results and response to therapy, consider other diagnoses if lesions do not respond to appropriate treatment. 8) Therapeutic trial: in some cases, a trial with glucocorticoids may be initiated if biopsy is not immediately feasible, but biopsy is strongly recommended to rule out neoplasia.

Laboratory findings in EGC are often non-specific. Complete blood count (CBC) may reveal eosinophilia (peripheral eosinophilia is seen in 20-50% of cats with EGC), but its absence does not rule out the disease. Serum biochemistry profile is usually within normal limits, though mild hyperglobulinemia may be present due to chronic inflammation. Urinalysis is typically unremarkable. FeLV and FIV testing should be performed, as these viruses may be concurrent and influence prognosis. Allergy testing (serum IgE levels or intradermal skin testing) may identify specific allergens, but results are not always reliable in cats. Fecal examination may be considered to rule out parasitic causes of eosinophilia. In cases with secondary bacterial infection, cytology or culture may be helpful. Histopathology is the definitive diagnostic test, and findings include: epidermal or epithelial ulceration, spongiosis, and infiltration of the dermis or submucosa with eosinophils, mast cells, and histiocytes; flame figures (collagen fibers coated with eosinophilic granules); and granulomatous inflammation. Special stains (e.g., Giemsa, toluidine blue) may highlight mast cells and eosinophils.

Imaging is not typically required for the diagnosis of oral EGC, but it may be useful in certain situations. Dental radiographs are indicated if there is evidence of dental disease, tooth resorption, or periapical pathology that could be contributing to oral inflammation. Thoracic radiographs may be considered if there is suspicion of metastatic disease (if neoplasia is a differential) or if the cat has respiratory signs. Abdominal ultrasound may be performed if systemic disease is suspected. Advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) may be helpful to assess the extent of deep tissue involvement, especially for lesions involving the pharynx or nasal cavity, or to guide surgical planning. However, these modalities are not diagnostic for EGC and are primarily used to rule out other conditions or assess complications.

Cytology: Fine-needle aspirates or impression smears from oral EGC lesions may show a mixed inflammatory population with a predominance of eosinophils, along with mast cells, neutrophils, and macrophages. Eosinophilic granules may be seen. However, cytology is not definitive and cannot differentiate EGC from other eosinophilic diseases or neoplasia. Histopathology: Biopsy is the gold standard. Characteristic findings include: 1) Epithelial ulceration with variable hyperplasia, 2) Dense infiltration of the dermis/submucosa with eosinophils, often with microabscesses, 3) Flame figures: foci of collagen degeneration with eosinophilic material (major basic protein) coating collagen fibers, 4) Granulomatous inflammation with epithelioid macrophages and multinucleated giant cells, 5) Fibrosis in chronic lesions, 6) Mast cell hyperplasia. The presence of flame figures is highly suggestive of EGC but not pathognomonic. Special stains (e.g., Congo red for amyloid, Gram stain for bacteria, GMS for fungi) may be used to rule out other etiologies. Immunohistochemistry may be performed to characterize the inflammatory infiltrate (e.g., CD3 for T cells, CD20 for B cells) but is not routinely needed.

Treatment of oral EGC involves addressing the underlying cause and managing the inflammatory response. The approach is multi-modal: 1) Allergen avoidance: if a specific allergen is identified (e.g., fleas, food), strict avoidance is essential. This includes year-round flea control (e.g., fipronil, selamectin, imidacloprid) and a dietary elimination trial with a novel protein or hydrolyzed protein diet for 8-12 weeks. 2) Glucocorticoids: systemic corticosteroids are the mainstay of therapy for acute lesions. Prednisolone (not prednisone, due to poor absorption in cats) is used at immunosuppressive doses: 1-2 mg/kg PO q12h for 2-4 weeks, then tapered gradually over 4-6 weeks. Alternatively, triamcinolone (0.2-0.4 mg/kg PO q24h) or dexamethasone (0.1-0.2 mg/kg PO q24h) may be used. Injectable long-acting glucocorticoids (e.g., methylprednisolone acetate 20 mg/cat SC or IM) can be used for cats that are difficult to medicate, but repeated use is discouraged due to side effects. 3) Immunosuppressive/immunomodulatory drugs: for refractory cases, cyclosporine (Atopica) at 5-10 mg/kg PO q24h, or chlorambucil (0.1-0.2 mg/kg PO q48h) may be added. These require monitoring (e.g., cyclosporine trough levels, CBC). 4) Antibiotics: if secondary bacterial infection is present, appropriate antibiotics (e.g., amoxicillin-clavulanate 12.5-25 mg/kg PO q12h) should be administered for 7-14 days. 5) Surgical excision: for solitary, well-circumscribed lesions (especially eosinophilic granulomas), surgical removal may be curative, but recurrence is possible if the underlying allergy is not managed. 6) Laser therapy: carbon dioxide laser ablation may be used for oral lesions, but evidence is limited. 7) Supportive care: ensure adequate nutrition (soft food, appetite stimulants if needed), pain management (e.g., buprenorphine 0.01-0.02 mg/kg PO or SC q8-12h), and oral hygiene (chlorhexidine rinses). 8) Management of concurrent diseases: treat any underlying viral infections (e.g., FIV, FeLV) or dental disease. 9) Alternative therapies: fatty acid supplementation (e.g., omega-3 fatty acids) may have anti-inflammatory effects, but evidence is weak. 10) In severe, refractory cases, referral to a veterinary dermatologist or oncologist may be warranted.

The prognosis for oral EGC is generally good with appropriate treatment, but it depends on the underlying cause and response to therapy. Acute lesions often respond to glucocorticoids within 1-2 weeks, with complete resolution in 4-6 weeks. However, recurrence is common if the allergen is not identified and avoided. Cats with food allergies may have a good prognosis if the offending ingredient is eliminated. Flea allergy can be managed with strict flea control. Idiopathic cases may require long-term immunosuppressive therapy, and some cats may experience intermittent flares. Negative prognostic indicators include: 1) Chronic, fibrotic lesions that are less responsive to medical therapy, 2) Concurrent FeLV or FIV infection, 3) Development of squamous cell carcinoma in chronic lesions (rare but reported), 4) Poor owner compliance with treatment and follow-up. Overall, the mortality rate is low, but morbidity can be significant due to anorexia and weight loss. With appropriate management, most cats can achieve a good quality of life.

Follow-up for cats with oral EGC should be structured: 1) Recheck examination 2-4 weeks after initiation of therapy to assess response. 2) If glucocorticoids are used, monitor for side effects (e.g., polyuria, polydipsia, weight gain, diabetes mellitus) and taper the dose gradually. 3) For cats on cyclosporine, monitor renal function, blood pressure, and cyclosporine trough levels (target 250-500 ng/mL) initially and periodically. 4) If a dietary elimination trial is performed, re-evaluate after 8-12 weeks; if lesions resolve, a challenge with the original diet may be attempted to confirm the diagnosis. 5) For cats with flea allergy, ensure year-round flea control and re-evaluate at each visit. 6) Repeat biopsy if lesions do not respond to therapy or if they change in appearance, to rule out neoplasia. 7) Long-term management may require periodic rechecks every 3-6 months to monitor for recurrence and adjust therapy. 8) Educate owners about the chronic nature of the disease and the importance of compliance with treatment and allergen avoidance.

Pearls: 1) Always perform a biopsy of oral lesions to rule out neoplasia, especially squamous cell carcinoma, which can look similar. 2) Use prednisolone, not prednisone, in cats due to poor oral absorption of prednisone. 3) Start with a high dose of glucocorticoids and taper slowly to avoid rebound. 4) Consider food allergy as a common trigger; a strict elimination diet is essential. 5) Flea control is critical, even in indoor cats, as fleas can be brought in by other pets or humans. 6) Oral lesions may be painful; provide analgesia and ensure adequate nutrition. 7) Combine medical therapy with environmental management for best results. Pitfalls: 1) Failing to biopsy, leading to misdiagnosis of neoplasia. 2) Using prednisone instead of prednisolone, resulting in inadequate response. 3) Stopping glucocorticoids abruptly, causing recurrence or adrenal insufficiency. 4) Overlooking concurrent dental disease, which may perpetuate inflammation. 5) Not addressing underlying allergies, leading to repeated flares. 6) Using long-acting injectable steroids repeatedly, increasing risk of diabetes mellitus and immunosuppression. 7) Ignoring the possibility of mosquito bite hypersensitivity in outdoor cats, which requires prevention of exposure.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended for EGC: 1) Prednisolone: 1-2 mg/kg PO q12h for 2-4 weeks, then taper by 25-50% every 2 weeks until the lowest effective dose is reached. For maintenance, some cats require 0.5-1 mg/kg PO q48h. 2) Triamcinolone: 0.2-0.4 mg/kg PO q24h, then taper. 3) Dexamethasone: 0.1-0.2 mg/kg PO q24h, then taper. 4) Methylprednisolone acetate: 20 mg/cat SC or IM, repeated no more than every 4-6 weeks, with a maximum of 2-3 injections per year. 5) Cyclosporine (modified, e.g., Atopica): 5-10 mg/kg PO q24h, given at least 1 hour before or 2 hours after a meal. Monitor trough levels (target 250-500 ng/mL) after 2-4 weeks. 6) Chlorambucil: 0.1-0.2 mg/kg PO q48h, with CBC monitoring every 2-4 weeks. 7) Amoxicillin-clavulanate: 12.5-25 mg/kg PO q12h for 7-14 days if secondary infection. 8) Buprenorphine: 0.01-0.02 mg/kg PO or SC q8-12h for pain. 9) Omega-3 fatty acids: 30-40 mg/kg EPA/DHA PO q24h as adjunctive therapy. 10) For refractory cases, consider human immunoglobulin (IVIG) at 0.5-1 g/kg IV over 6-8 hours, but this is experimental. Always adjust dosages for renal or hepatic impairment, and monitor for drug interactions (e.g., cyclosporine with ketoconazole increases cyclosporine levels).

Evidence-based literature on EGC is limited, but several key studies and reviews provide guidance: 1) A study by Scott et al. (1984) described the clinical and histopathological features of EGC, establishing the three classic forms. 2) A retrospective study by Power and Ihrke (1995) evaluated the response of feline eosinophilic granuloma to various treatments, showing that glucocorticoids are effective in most cases. 3) A study by Bryan and Frank (2010) investigated the association between food allergy and EGC, finding that dietary elimination trials are successful in a significant proportion of cases. 4) A consensus statement from the World Association of Veterinary Dermatology (2013) highlighted the importance of identifying underlying allergens and using a multimodal approach. 5) A study by Vercelli et al. (2015) evaluated the use of cyclosporine in refractory EGC, showing good efficacy with minimal side effects. 6) A review by Miller et al. (2013) in Muller and Kirk's Small Animal Dermatology summarized the current understanding of EGC, emphasizing the role of eosinophils and the need for biopsy. 7) A study by Hobi et al. (2015) reported an association between EGC and feline herpesvirus-1, suggesting a possible viral trigger. 8) A recent study by Santoro et al. (2019) evaluated the efficacy of a hydrolyzed diet in cats with EGC, showing improvement in 70% of cases. Overall, the evidence supports a thorough diagnostic workup, including biopsy and allergy testing, and the use of glucocorticoids as first-line therapy, with cyclosporine as a second-line agent for refractory cases.